[Overexpression of the long non-coding RNA ADAMTS9-AS2 suppresses colorectal cancer proliferation and metastasis].


Journal

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
ISSN: 1672-7347
Titre abrégé: Zhong Nan Da Xue Xue Bao Yi Xue Ban
Pays: China
ID NLM: 101230586

Informations de publication

Date de publication:
28 Jul 2019
Historique:
entrez: 16 8 2019
pubmed: 16 8 2019
medline: 24 8 2019
Statut: ppublish

Résumé

To investigate the expression, clinical significance, and biological function of the long non-coding RNA (lncRNA) ADAMTS9-AS2 in colorectal cancer (CRC).
 Methods: Gene microarray analysis was performed to explore the expression of ADAMTS9-AS2 in CRC. Real-time PCR was used to verify its expression in 20-paired CRC tissues and adjacent non-tumor tissues. We further explored the relationship between ADAMTS9-AS2 expression and clinicopathological features, and its prognostic role in relapse-free survival (RFS) among early stage CRC patients using Kaplan-Meier and Cox regression analyses. In vitro assays, cell counting kit-8 assay, colony formation assay, and Transwell assay were used to evaluate the biological function of ADAMTS9-AS2 in CRC.
 Results: ADAMTS9-AS2 was down-regulated in CRC patients according to the gene microarray analysis, which was confirmed in CRC tissues and cells. High expression of ADAMTS9-AS2 was associated with a higher 5-year RFS rate (83.8% vs 73.5%, P=0.041) and it was an independent prognostic factor for RFS [hazard ratio (HR)=0.528; 95% CI 0.299 to 0.932; P=0.028] at the early stage of CRC. ADAMTS9-AS2 overexpression in CRC cells inhibited cell proliferation, migration, and invasion, while suppression of ADAMTS9-AS2 showed opposite effects.
 Conclusion: ADAMTS9-AS2 is a valuable prognostic factor for CRC and may function as a tumor suppressor in CRC via inhibiting cell proliferation and metastasis. 目的:探讨长链非编码RNA(long non-coding RNA,lncRNA)ADAMTS9-AS2在结直肠癌(colorectal cancer,CRC)中的表达、临床意义和生物学作用。方法:利用基因芯片数据分析CRC中ADAMTS9-AS2的表达情况,并利用real-time PCR技术在20例CRC组织和癌旁正常组织及细胞系中进行验证。利用基因芯片提供的临床数据进行临床病理特征相关性分析、Kaplan-Meier生存分析和Cox回归分析。利用CCK-8、克隆形成和Transwell迁移和侵袭实验检测ADAMTS9-AS2对CRC细胞增殖、迁移和侵袭能力的影响。结果:ADAMTS9-AS2在CRC组织和细胞中显著低表达(P<0.05),其表达高低与早期CRC患者的年龄、性别、分期、病灶位置和错配修复状态均无明显相关性(P>0.05)。在早期CRC患者中,ADAMTS9-AS2高表达组患者的5年无复发生存率高于低表达组(83.8% vs 73.5%,P=0.041),ADAMTS9-AS2高表达是CRC患者无复发生存的独立保护因素(风险比=0.528,95% CI:0.299~0.932;P=0.028)。ADAMTS9-AS2表达上调能明显抑制CRC细胞的增殖和转移(P<0.05),表达下调则导致相反的结果(P<0.05)。结论:ADAMTS9-AS2通过抑制CRC细胞的增殖和转移发挥抑癌基因的作用,是CRC重要的预后因素。.

Autres résumés

Type: Publisher (chi)
目的:探讨长链非编码RNA(long non-coding RNA,lncRNA)ADAMTS9-AS2在结直肠癌(colorectal cancer,CRC)中的表达、临床意义和生物学作用。方法:利用基因芯片数据分析CRC中ADAMTS9-AS2的表达情况,并利用real-time PCR技术在20例CRC组织和癌旁正常组织及细胞系中进行验证。利用基因芯片提供的临床数据进行临床病理特征相关性分析、Kaplan-Meier生存分析和Cox回归分析。利用CCK-8、克隆形成和Transwell迁移和侵袭实验检测ADAMTS9-AS2对CRC细胞增殖、迁移和侵袭能力的影响。结果:ADAMTS9-AS2在CRC组织和细胞中显著低表达(P<0.05),其表达高低与早期CRC患者的年龄、性别、分期、病灶位置和错配修复状态均无明显相关性(P>0.05)。在早期CRC患者中,ADAMTS9-AS2高表达组患者的5年无复发生存率高于低表达组(83.8% vs 73.5%,P=0.041),ADAMTS9-AS2高表达是CRC患者无复发生存的独立保护因素(风险比=0.528,95% CI:0.299~0.932;P=0.028)。ADAMTS9-AS2表达上调能明显抑制CRC细胞的增殖和转移(P<0.05),表达下调则导致相反的结果(P<0.05)。结论:ADAMTS9-AS2通过抑制CRC细胞的增殖和转移发挥抑癌基因的作用,是CRC重要的预后因素。.

Identifiants

pubmed: 31413211
doi: 10.11817/j.issn.1672-7347.2019.190142
doi:

Substances chimiques

RNA, Long Noncoding 0
ADAMTS9 Protein EC 3.4.24.-
ADAMTS9 protein, human EC 3.4.24.-

Types de publication

Journal Article

Langues

chi

Sous-ensembles de citation

IM

Pagination

741-748

Auteurs

Xiaoyun Bu (X)

Department of Colorectal Surgery, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.

Ang Qin (A)

Department of Endoscopic Medical Center, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.

Zhi Luo (Z)

Department of Colorectal Surgery, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.

Yingbin Hu (Y)

Department of Colorectal Surgery, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH